AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. Co.'s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. Co. has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. Co. is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. We show 16 historical shares outstanding datapoints in our coverage of ABCL's shares outstanding history.
Understanding the changing numbers of ABCL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABCL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABCL by allowing them to research ABCL shares outstanding history
as well as any other stock in our coverage universe. |
Free ABCL Email Alerts:
Video: Shares Outstanding Importance
